Example: Heart Attack

Search clinical trials for: Modulation of FiO2

Total 10000 results

NCT01623869

Completed

Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Angiosarcoma
NCT00759603

Completed

Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma
NCT02520219

Unknown

Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study

Peripheral T-cell Lymphomas
NCT01498003

Completed

Tirofiban in Stenting for Long Coronary Lesion (PETITION)

Coronary Artery Disease
NCT02375022

Unknown

Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

Lung Cancer
NCT02347358

Unknown

Mechanical Opening Device Implantation Following Intravenous r-tPA for Recanalization in Acute Ischemic Stroke

Ischemic Cerebrovascular Accident
NCT00019123

Completed

Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma

Sarcoma
NCT00016224

Completed

Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer

Ovarian Cancer
NCT00030550

Completed

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms
NCT00718224

Completed

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery (SAVE-KNEE)

Venous Thromboembolism
NCT00489840

Completed

Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate (CSC-AA)

Chronic Central Serous Chorioretinopathy
NCT01094340

Unknown

Thalidomide for Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease
NCT01507077

Completed

ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity

Obesity
NCT00100685

Terminated

Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma | Metastases
NCT00953615

Terminated

Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)

Primary Sclerosing Cholangitis
NCT00482495

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm
NCT01266707

Unknown

Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma

Hepatocellular Carcinoma
NCT00413504

Completed

Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism

Deep Vein Thrombosis | Pulmonary Embolism
NCT00001680

Completed

A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus

Discoid Lupus Erythematosus
NCT00001446

Completed

A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

Prostatic Neoplasm
NCT00002392

Completed

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

HIV Infections
NCT06098755

Withdrawn

The Sequestration of Holistic Stress Management Techniques for Adults

Depression | PTSD | Hypertension | Fatigue | Arthritis | Rheumatoid Arthritis | Migraine | Anemia | Hyperthyroidism | Anxiety
NCT07071844

Not yet recruiting

BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients (BETWEEN)

Metastatic Colorectal Cancer
NCT06992648

Recruiting

Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer (REGTAS-2)

Colorectal Cancer Metastatic | Colorectal Cancer Recurrent
NCT06801730

Recruiting

Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma (NALIRIBVRG)

Glioma
NCT06763094

Not yet recruiting

Efficacy of Calcium Dobesilate Versus Tranexamic Acid for Treating Heavy Menstrual Bleeding

Menorrhagia | Abnormal Uterine Bleeding
NCT06788171

Not yet recruiting

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

Colorectal Cancer Liver Metastasis
NCT06873763

Recruiting

Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer

Metastatic Colorectal Cancer (CRC) | Recurrent Colorectal Cancer
NCT06163820

Recruiting

Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases (BETTER)

Melanoma Brain Metastases
NCT06156527

Recruiting

A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker

Lazertinib
NCT05685836

Recruiting

89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

Neurofibromatosis 2
NCT05325229

Recruiting

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

Platinum-resistant Recurrent Ovarian Cancer
NCT05278715

Recruiting

Modified CV Regimen in Optic Pathway Glioma

Optic Glioma | Pediatric Brain Tumor, Optic Nerve Glioma
NCT04973904

Not yet recruiting

Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer

Cervical Cancer
NCT05332821

Completed

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC (CHANCE2201)

Hepatocellular Carcinoma
NCT03239145

Completed

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Advanced Solid Tumor
NCT02711553

Active, not recruiting

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Metastatic Cancer | Advanced Cancer | Biliary Tract Cancer
NCT00780494

Completed

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Stomach Cancer | Gastrointestinal Stromal Tumor (GIST) | Gastric (Stomach) Cancer | Neoplasm of Cardioesophageal Junction
NCT03829410

Completed

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation

Metastatic Colorectal Cancer | KRAS Gene Mutation
NCT03452579

Active, not recruiting

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

Glioblastoma
NCT00444535

Completed

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Neoplasms, Breast
NCT01740258

Completed

Bevacizumab Beyond Progression (BBP) (BBP)

Glioblastoma | Malignant Glioma | Gliosarcoma | Grade 4 Malignant Glioma
NCT00794417

Terminated

A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma

Non-small Cell Lung Cancer | Advanced Carcinoma
NCT00979992

Completed

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma
NCT00614679

Completed

A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia

End-Stage Renal Disease | Hemodialysis Catheter-associated Infection
NCT01739218

Completed

A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable (ANTHALYA)

Ovarian Cancer
NCT00217581

Completed

Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer
NCT01181102

Completed

A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

Venous Thromboembolism
NCT01750983

Completed

Ipilimumab and Lenalidomide in Advanced Cancer

Advanced Cancers
NCT00428922

Completed

Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients

Breast Cancer

Search clinical trials for: Modulation of FiO2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations